Literature DB >> 12100087

Study of an adenosine A1 receptor agonist on trigeminally evoked dural blood vessel dilation in the anaesthetized rat.

A C Honey1, P A Bland-Ward, H E Connor, W Feniuk, P P A Humphrey.   

Abstract

The purpose of this study was to use intravital microscopy to determine the effect of a selective adenosine A1 receptor agonist, GR79236 (1, 3 and 10 microg/kg i.v.), on neurogenic dural blood vessel dilation in anaesthetized rats. Vasodilation was evoked either by electrical stimulation of perivascular trigeminal nerves or by intravenous CGRP. GR79236 (1-10 microg/kg i.v.) caused a dose-dependent inhibition of neurogenic vasodilation, but had no significant effect on dural vasodilation caused by CGRP. GR79236 (1-3 microg/kg i.v.) had no effect on basal dural vessel diameter, but caused transient dose-dependant bradycardia and hypotension. Bradycardia was more prolonged following 10 microg/kg i.v. GR79236. Pre-treatment with the adenosine A1 receptor antagonist DPCPX (1 mg/kg i.v.) prevented the inhibitory effect of GR79236 (10 microg/kg i.v.) on neurogenic vasodilation as well as GR79236-induced bradycardia and hypotension. These data suggest that the inhibition of neurogenic vasodilation by GR79236 is mediated via the activation of prejunctional adenosine A1 receptors. Provided the systemic cardiovascular effects could be limited, such a mechanism may offer a novel approach to migraine therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12100087     DOI: 10.1046/j.1468-2982.2002.00345.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  8 in total

1.  CSD-Induced Arterial Dilatation and Plasma Protein Extravasation Are Unaffected by Fremanezumab: Implications for CGRP's Role in Migraine with Aura.

Authors:  Aaron J Schain; Agustin Melo-Carrillo; Jennifer Stratton; Andrew M Strassman; Rami Burstein
Journal:  J Neurosci       Date:  2019-05-24       Impact factor: 6.167

2.  Pharmacology.

Authors:  Hayrunnisa Bolay; Paul Durham
Journal:  Handb Clin Neurol       Date:  2010

3.  Inhibitory effect of BIBN4096BS on cephalic vasodilatation induced by CGRP or transcranial electrical stimulation in the rat.

Authors:  Kenneth A Petersen; Steffen Birk; Henri Doods; Lars Edvinsson; Jes Olesen
Journal:  Br J Pharmacol       Date:  2004-10-25       Impact factor: 8.739

Review 4.  Animal migraine models for drug development: status and future perspectives.

Authors:  Inger Jansen-Olesen; Peer Tfelt-Hansen; Jes Olesen
Journal:  CNS Drugs       Date:  2013-12       Impact factor: 5.749

Review 5.  Current and prospective pharmacological targets in relation to antimigraine action.

Authors:  Suneet Mehrotra; Saurabh Gupta; Kayi Y Chan; Carlos M Villalón; David Centurión; Pramod R Saxena; Antoinette MaassenVanDenBrink
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-15       Impact factor: 3.000

6.  Characterization of the trigeminovascular actions of several adenosine A2A receptor antagonists in an in vivo rat model of migraine.

Authors:  Kristian A Haanes; Alejandro Labastida-Ramírez; Kayi Y Chan; René de Vries; Brian Shook; Paul Jackson; Jimmy Zhang; Christopher M Flores; Alexander H J Danser; Carlos M Villalón; Antoinette MaassenVanDenBrink
Journal:  J Headache Pain       Date:  2018-05-25       Impact factor: 7.277

Review 7.  Involvement of adenosine signaling pathway in migraine pathophysiology: a systematic review of preclinical studies.

Authors:  Janu Thuraiaiyah; Lili Kokoti; Mohammad Al-Mahdi Al-Karagholi; Messoud Ashina
Journal:  J Headache Pain       Date:  2022-04-05       Impact factor: 7.277

Review 8.  Post-triptan era for the treatment of acute migraine.

Authors:  Peter J Goadsby
Journal:  Curr Pain Headache Rep       Date:  2004-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.